Sanofi is experiencing active shortages of Myozyme and Nexviazyme, two critical enzyme replacement therapies used to treat Pompe disease, according to reporting by STAT. The supply chain disruption emerged shortly after the U.S. Food and Drug Administration issued a warning letter to the drugmaker regarding manufacturing issues at its Irish production facility in Waterford.
Manufacturing Bottlenecks Hit Pompe Disease Treatments
According to STAT, Sanofi recently alerted patient advocacy groups and physicians across the United States and Europe regarding the dwindling supplies. Myozyme serves as an older standard of care, while Nexviazyme represents a newer therapeutic option for patients diagnosed with the rare genetic disorder. The supply deficits stem from a combination of quality control issues at the Waterford plant and a bottleneck occurring during the final manufacturing phase.
Did you know?
Jazz Pharmaceuticals Expands Rare Disease Pipeline
In a separate pharmaceutical industry development, Jazz Pharmaceuticals has agreed to acquire Actio Biosciences in a transaction valued at up to $1.32 billion, according to Reuters. The acquisition brings an experimental therapy known as ABS-1230 into the company’s development pipeline. ABS-1230 targets KCNT1-related epilepsy, a severe inherited condition characterized by frequent seizures and developmental challenges in pediatric patients.
Data cited by Reuters indicates that KCNT1-related epilepsy impacts approximately 2,500 individuals in the United States. While no approved therapies currently exist for this specific genetic form of epilepsy, ABS-1230 successfully reduced seizure frequency in an early-stage study involving children. The therapy is now progressing into further clinical evaluation designed to support an official U.S. approval application.
Frequently Asked Questions
What caused the Sanofi Pompe disease drug shortages?
According to STAT, the shortages of Myozyme and Nexviazyme are driven by a final-phase manufacturing bottleneck and quality control issues at Sanofi’s Waterford facility in Ireland.
Which regulatory agency warned Sanofi over manufacturing issues?
The U.S. Food and Drug Administration issued a warning letter to Sanofi regarding the Waterford plant, as reported by STAT.
What is the acquisition value of Actio Biosciences by Jazz Pharmaceuticals?
According to Reuters, Jazz Pharmaceuticals agreed to buy Actio Biosciences for up to $1.32 billion.
How many patients are affected by KCNT1-related epilepsy in the U.S.?
According to Reuters, the condition affects approximately 2,500 patients in the United States.
Stay Informed on Healthcare Developments
Explore our latest coverage on biopharma trends, regulatory updates, and rare disease research. Share your thoughts in the comments below.
Related reading